Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 2, 2012, Pages 622-632

  Weikel, Karen A ^a   FitzGerald, Paul ^b   Shang, Fu ^a   Andrea Caceres, M ^a   Bian, Qingning ^a   Handa, James T ^c   Stitt, Alan W ^d   Taylor, Allen ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COLLAGEN; LIPOFUSCIN; MELANIN;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BRUCH MEMBRANE; CELL VACUOLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE MODEL; DISEASE SEVERITY; GLYCEMIC INDEX; IMMUNOHISTOCHEMISTRY; MALE; MORBIDITY; MOUSE; NONHUMAN; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TRANSMISSION ELECTRON MICROSCOPY; AGING; ANIMAL; C57BL MOUSE; CARBOHYDRATE DIET; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; METABOLISM; PATHOLOGY; RETINA; RETINA MACULA DEGENERATION; ULTRASTRUCTURE;

AGING; ANIMALS; DIETARY CARBOHYDRATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; MACULAR DEGENERATION; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; RETINA;

EID: 84858992894     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8545     Document Type: Article

References (134)

1. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38:450-471.
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
5. Friberg TR, Tolentino M, Weber P, Patel S, Campbell S, Goldbaum M. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol. 2010;94:1611-1617.
6. Forte R, Cennamo G, Finelli M, et al. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization. Acta Ophthalmol. 2010;88:e305-e310.
7. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomized double masked study. BMJ. 2010;340:c2459.
8. Biarnes M, Mones J, Alonso J, Arias L. Update on geographic atrophy in age-related macular degeneration. Optom Vis Sci. 2011.
9. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007;125:544-550.
10. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129:75-80.
11. Ivers RQ, Norton R, Cumming RG, Butler M, Campbell AJ. Visual impairment and risk of hip fracture. Am J Epidemiol. 2000;152: 633-639.
12. Desrosiers J, Wanet-Defalque MC, Temisjian K, et al. Participation in daily activities and social roles of older adults with visual impairment. Disabil Rehabil. 2009;31:1227-1234.
13. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348:145-149.
14. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116:514-520.
15. Wood J, Lacherez P, Black A, Cole M, Boon M, Kerr G. Risk of falls, injurious falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:5088-5092.
16. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials 2004;1:91-107.
17. Chiu CJ, Taylor A. Nutritional antioxidants and age-related cataract and maculopathy. Exp Eye Res. 2007;84:229-245.
18. Ma L, Lin XM. Effects of lutein and zeaxanthin on aspects of eye health. J Sci Food Agric. 2010;90:2-12.
19. Coleman H, Chew E. Nutritional supplementation in age-related macular degeneration. Curr Opin Ophthalmol. 2007;18:220-223.
20. Weikel KA, Taylor A. Nutritional modulation of age-related macular degeneration. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology. Lippincott, Williams & Wilkins; 2011.
21. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials 1999;20:573-600.
22. Chew EY, Lindblad AS, Clemons T. Summary results and recommendations from the age-related eye disease study. Arch Ophthalmol. 2009;127:1678-1679.
23. Chiu CJ, Milton RC, Klein R, Gensler G, Taylor A. Dietary carbohydrate and the progression of age-related macular degeneration: a prospective study from the Age-Related Eye Disease Study. Am J Clin Nutr. 2007;86:1210-1218.
24. Chiu CJ, Milton RC, Gensler G, Taylor A. Association between dietary glycemic index and age-related macular degeneration in nondiabetic participants in the Age-Related Eye Disease Study. Am J Clin Nutr. 2007;86:180-188.
25. Chiu CJ, Klein R, Milton RC, Gensler G, Taylor A. Does eating particular diets alter risk of age-related macular degeneration in users of the Age-Related Eye Disease Study supplements? Br J Ophthalmol. 2009;1241-1246.
26. Chiu CJ, Hubbard LD, Armstrong J, et al. Dietary glycemic index and carbohydrate in relation to early age-related macular degeneration. Am J Clin Nutr. 2006;83:880-886.
27. Kaushik S, Wang JJ, Flood V, et al. Dietary glycemic index and the risk of age-related macular degeneration. Am J Clin Nutr. 2008; 88:1104-1110.
28. Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34:362-366.
29. Ferland A, Brassard P, Lemieux S, et al. Impact of high-fat/lowcarbohydrate, high-, low-glycaemic index or low-caloric meals on glucose regulation during aerobic exercise in type 2 diabetes. Diabet Med. 2009;26:589-595.
30. Jenkins DJ, Kendall CW, McKeown-Eyssen G, et al. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA. 2008;300:2742-2753.
31. McKeown NM, Meigs JB, Liu S, et al. Dietary carbohydrates and cardiovascular disease risk factors in the Framingham offspring cohort. J Am Coll Nutr. 2009;28:150-158.
32. Liu S, Stampfer MJ, Hu FB, et al. Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. Am J Clin Nutr. 1999;70:412-419.
33. Riegersperger M, Sunder-Plassmann G. How to prevent progression to end stage renal disease. J Ren Care. 2007;33:105-107.
34. Gopinath B, Harris DC, Flood VM, Burlutsky G, Brand-Miller J, Mitchell P. Carbohydrate nutrition is associated with the 5-year incidence of chronic kidney disease. J Nutr. 2011;141:433-439.
35. Wolever TM, Jenkins DJ, Vuksan V, Jenkins AL, Wong GS, Josse RG. Beneficial effect of low-glycemic index diet in overweight NIDDM subjects. Diabetes Care. 1992;15:562-564.
36. Sakurai M, Nakamura K, Miura K, et al. Dietary glycemic index and risk of type 2 diabetes mellitus in middle-aged Japanese men. Metabolism. 2012;61:47-55.
37. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: a review. Diabetologia. 2001;44:129-146.
38. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676-683.
39. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005;15:16R-28R.
40. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949-955.
41. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest. 1993;91:2155-2168.
42. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96: 1395-1403.
43. Miyata T, Hori O, Zhang J, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996; 98:1088-1094.
44. Owen WF Jr, Hou FF, Stuart RO, et al. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 1998;53:1365-1373.
45. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest.2003;111:959-972.
46. Che W, Asahi M, Takahashi M, et al. Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells: the involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes. J Biol Chem.1997;272:18453-18459.
47. Makita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara H, Koike T. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrol Dial Transplant. 1996; 11(suppl 5):31-33.
48. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus, I: the AGE concept. Cardiovasc Res. 1998;37:586-600.
49. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457-468.
50. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol. 1998;153:1149-1155.
51. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 1992;15:1835-1843.
52. Sugiyama S, Miyata T, Ueda Y, et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol. 1998;9:1681-1688.
53. Kilhovd BK, Giardino I, Torjesen PA, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism. 2003;52: 163-167.
54. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis. 2009;205:590-594.
55. Fosmark DS, Berg JP, Jensen AB, et al. Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone. Acta Ophthalmol. 2009;87:498-500.
56. Han Y, Randell E, Vasdev S, et al. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with type 1 diabetes. Clin Biochem. 2009;42:562-569.
57. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem. 1992;267:10211-10214.
58. Snow LM, Fugere NA, Thompson LV. Advanced glycation endproduct accumulation and associated protein modification in type II skeletal muscle with aging. J Gerontol A Biol Sci Med Sci. 2007;62:1204-1210.
59. Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore Longitudinal Study of Aging. J Ren Nutr. 2010;20:74-81.
60. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community- dwelling adults. J Am Geriatr Soc. 2009;57:1874-1880.
61. Howes K, Liu Y, Dunaief J, et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:3713-3720.
62. Torreggiani M, Liu H, Wu J, et al. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol. 2009;175:1722-1732.
63. Hofmann SM, Dong HJ, Li Z, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002;51:2082-2089.
64. Cai W, He JC, Zhu L, et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol. 2008;173:327-336.
65. Vlassara H, Cai W, Goodman S, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor- 1. J Clin Endocrinol Metab. 2009;94:4483-4491.
66. Ma W, Lee SE, Guo J, et al. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2007;48: 1355-1361.
67. Neumann A, Schinzel R, Palm D, Riederer P, Munch G. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-κB activation and cytokine expression. FEBS Lett. 1999;453:283-287.
68. Sato T, Wu X, Shimogaito N, Takino J, Yamagishi S, Takeuchi M. Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys. Eur J Nutr. 2009;48:6-11.
69. Chiarelli F, de Martino M, Mezzetti A, et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr. 1999;134:486-491.
70. Kostolanska J, Jakus V, Barak L. HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2009;22:433-442.
71. Rakoczy EP, Yu MJ, Nusinowitz S, Chang B, Heckenlively JR. Mouse models of age-related macular degeneration. Exp Eye Res. 2006;82:741-752.
72. Espinosa-Heidmann DG, Suner IJ, Catanuto P, Hernandez EP, Marin-Castano ME, Cousins SW. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci. 2006;47: 729-737.
73. Mishima H, Hasebe H. Some observations in the fine structure of age changes of the mouse retinal pigment epithelium. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978;209:1-9.
74. Sarks S, Cherepanoff S, Killingsworth M, Sarks J. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:968-977.
75. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009; 106:18751-18756.
76. Provost AC, Vede L, Bigot K, et al. Morphologic and electroretinographic phenotype of SR-BI knockout mice after a long-term atherogenic diet. Invest Ophthalmol Vis Sci. 2009;50:3931-3942.
77. Bonilha VL. Age and disease-related structural changes in the retinal pigment epithelium. Clin Ophthalmol. 2008;2:413-424.
78. Cherepanoff S, McMenamin P, Gillies MC, Kettle E, Sarks SH. Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol. 2010; 94:918-925.
79. Spraul CW, Grossniklaus HE. Characteristics of Drusen and Bruch's membrane in postmortem eyes with age-related macular degeneration. Arch Ophthalmol. 1997;115:267-273.
80. Mishima H, Kondo K. Ultrastructure of age changes in the basal infoldings of aged mouse retinal pigment epithelium. Exp Eye Res. 1981;33:75-84.
81. Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol. 1999;117:329-339.
82. Curcio CA, Presley JB, Millican CL, Medeiros NE. Basal deposits and drusen in eyes with age-related maculopathy: evidence for solid lipid particles. Exp Eye Res. 2005;80:761-775.
83. Fujihara M, Bartels E, Nielsen LB, Handa JT. A human apoB100 transgenic mouse expresses human apoB100 in the RPE and develops features of early AMD. Exp Eye Res. 2009;88:1115-1123.
84. Katz ML, Robison WG Jr. Age-related changes in the retinal pigment epithelium of pigmented rats. Exp Eye Res. 1984;38: 137-151.
85. Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets. 2009;13:641-651.
86. Sundelin SP, Nilsson SE, Brunk UT. Lipofuscin-formation in cultured retinal pigment epithelial cells is related to their melanin content. Free Radic Biol Med. 2001;30:74-81.
87. Rozanowski B, Cuenco J, Davies S, et al. The phototoxicity of aged human retinal melanosomes. Photochem Photobiol. 2008; 84:650-657.
88. van der Schaft TL, de Bruijn WC, Mooy CM, Ketelaars DA, de Jong PT. Is basal laminar deposit unique for age-related macular degeneration? Arch Ophthalmol. 1991;109:420-425.
89. Tuo J, Bojanowski CM, Zhou M, et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:3827-3836.
90. Sparrow JR. Bisretinoids of RPE lipofuscin: trigger for complement activation in age-related macular degeneration. Adv Exp Med Biol. 2010;703:63-74.
91. Luhmann UF, Robbie S, Munro PM, et al. The drusenlike phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages. Invest Ophthalmol Vis Sci. 2009;50:5934-5943.
92. Xu H, Chen M, Manivannan A, Lois N, Forrester JV. Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. Aging Cell. 2008;7:58-68.
93. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80:595-606.
94. Isken F, Weickert MO, Tschop MH, et al. Metabolic effects of diets differing in glycaemic index depend on age and endogenous glucose-dependent insulinotrophic polypeptide in mice. Diabetologia. 2009;52:2159-2168.
95. Isken F, Klaus S, Petzke KJ, Loddenkemper C, Pfeiffer AF, Weickert MO. Impairment of fat oxidation under high vs low glycemic index diet occurs prior to the development of an obese phenotype. Am J Physiol Endocrinol Metab. 2010;298:E297-E295.
96. Zhao Z, Chen Y, Wang J, et al. Age-related retinopathy in NRF2- deficient mice. PLoS One. 2011;6:e19456.
97. Marin-Castano ME, Striker GE, Alcazar O, Catanuto P, Espinosa- Heidmann DG, Cousins SW. Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci. 2006;47:4098-4112.
98. Ida H, Ishibashi K, Reiser K, Hjelmeland LM, Handa JT. Ultrastructural aging of the RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse. Invest Ophthalmol Vis Sci. 2004;45:2348-2354.
99. Takai H, Kato A, Ishiguro T, et al. Optimization of tissue processing for immunohistochemistry for the detection of human glypican- 3. Acta Histochem. 2010;112:240-250.
100. Ha SK, Choi C, Chae C. Development of an optimized protocol for the detection of classical swine fever virus in formalin-fixed, paraffin-embedded tissues by seminested reverse transcriptionpolymerase chain reaction and comparison with in situ hybridization. Res Vet Sci. 2004;77:163-169.
101. Evke E, Minbay FZ, Temel SG, Kahveci Z. Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave- assisted antigen retrieval. J Mol Histol. 2009;40:13-21.
102. Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:1544-1552.
103. Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br J Ophthalmol. 1999;83:358-368.
104. Marmorstein LY, McLaughlin PJ, Peachey NS, Sasaki T, Marmorstein AD. Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: a model for the early pathogenic course of macular degeneration. Hum Mol Genet. 2007;16:2423-2432.
105. Weiter JJ, Delori FC, Wing GL, Fitch KA. Retinal pigment epithelial lipofuscin and melanin and choroidal melanin in human eyes. Invest Ophthalmol Vis Sci. 1986;27:145-152.
106. Uchiki T, Weikel KA, Jiao W, et al. Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in non diabetics). Aging Cell. 2012;11:1-13.
107. Rabbani N, Thornalley PJ. Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids. In press.
108. Justilien V, Pang JJ, Renganathan K, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci. 2007;48: 4407-4420.
109. Fujihara M, Nagai N, Sussan TE, Biswal S, Handa JT. Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice. PLoS ONE. 2008;3:e3119.
110. Tso MO. Pathogenetic factors of aging macular degeneration. Ophthalmology. 1985;92:628-635.
111. Lewis H, Straatsma BR, Foos RY, Lightfoot DO. Reticular degeneration of the pigment epithelium. Ophthalmology. 1985;92: 1485-1495.
112. Sarks SH. Ageing and degeneration in the macular region: a clinicopathologic study. Br J Ophthalmol. 1976;60:324-341.
113. Picard E, Ranchon-Cole I, Jonet L, et al. Light-induced retinal degeneration correlates with changes in iron metabolism gene expression, ferritin level, and aging. Invest Ophthalmol Vis Sci. 2011;52:1261-1274.
114. Ader M, Bergman RN. Insulin sensitivity in the intact organism. Baillieres Clin Endocrinol Metab. 1987;1:879-910.
115. Anderson GH, Cho CE, Akhavan T, Mollard RC, Luhovyy BL, Finocchiaro ET. Relation between estimates of cornstarch digestibility by the Englyst in vitro method and glycemic response, subjective appetite, and short-term food intake in young men. Am J Clin Nutr. 2011;91:932-939.
116. So PW, Yu WS, Kuo YT, et al. Impact of resistant starch on body fat patterning and central appetite regulation. PLoS One. 2007;2: e1309.
117. Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN. Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr. 2005;82:559-567.
118. Brouwers O, Niessen PM, Haenen G, et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia. 2010;53:989-1000.
119. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet. 2002;359:2072-2077.
120. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-494.
121. Omri S, Behar-Cohen F, de Kozak Y, et al. Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy role of PKCzeta in the Goto Kakizaki rat model. Am J Pathol. 2011;179:942-953.
122. Tso MO, Cunha-Vaz JG, Shih CY, Jones CW. Clinicopathologic study of blood-retinal barrier in experimental diabetes mellitus. Arch Ophthalmol. 1980;98:2032-2040.
123. Arnal E, Miranda M, Johnsen-Soriano S, et al. Beneficial effect of docosahexanoic acid and lutein on retinal structural, metabolic, and functional abnormalities in diabetic rats. Curr Eye Res. 2009; 34:928-938.
124. Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia. 2010;53:971-979.
125. Tang L, Zhang Y, Jiang Y, et al. Dietary wolfberry ameliorates retinal structure abnormalities in db/db mice at the early stage of diabetes. Exp Biol Med (Maywood). 2011;236:1051-1063.
126. Sohn EJ, Kim YS, Kim CS, Lee YM, Kim JS. KIOM-79 prevents apoptotic cell death and AGEs accumulation in retinas of diabetic db/db mice. J Ethnopharmacol. 2009;121:171-174.
127. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.
128. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun. 2000;3:380-388.
129. Mamputu JC, Renier G. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells: inhibitory effect of gliclazide. J Diabetes Complications. 2002; 16:284-293.
130. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
131. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.
132. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes. 1996;45(suppl 3):S65-S66.
133. Yamagishi S, Nakamura K, Matsui T, et al. Pigment epitheliumderived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem. 2006;281:20213-20220.
134. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002;16:1928-1930.